Bortezomib induced purpuric rash
Corresponding Author
Zoe Apalla
Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Correspondence
Zoe Apalla, Second Dermatology Department, Aristotle University of Thessaloniki, 124 Delfon str, PC 54643, Thessaloniki, Greece.
Email: [email protected]
Search for more papers by this authorMattheos Bobos
Private Dermatopathology Laboratory, Thessaloniki, Greece
Search for more papers by this authorAimilios Lallas
Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Search for more papers by this authorElizabeth Lazaridou
Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Search for more papers by this authorEirini Katodritou
Haematology Department, “Theagenio” Hospital, Thessaloniki, Greece
Search for more papers by this authorCorresponding Author
Zoe Apalla
Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Correspondence
Zoe Apalla, Second Dermatology Department, Aristotle University of Thessaloniki, 124 Delfon str, PC 54643, Thessaloniki, Greece.
Email: [email protected]
Search for more papers by this authorMattheos Bobos
Private Dermatopathology Laboratory, Thessaloniki, Greece
Search for more papers by this authorAimilios Lallas
Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Search for more papers by this authorElizabeth Lazaridou
Second Dermatology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
Search for more papers by this authorEirini Katodritou
Haematology Department, “Theagenio” Hospital, Thessaloniki, Greece
Search for more papers by this author
REFERENCES
- 1Peterlin P, Ponge T, Blin N, Moreau P, Hamidou M, Agard C. Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report. Clin Lymphoma Myeloma Leuk. 2011; 11: 373-374.
- 2Ichiyama S, Funasaka Y, Yamashita H, Tamura H, Inokuchi K, Saeki H. Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: a case report. Allergol Int. 2017; 66: 497-498.
- 3Ransohoff JD, Kwong BY. Cutaneous adverse events of targeted therapies for hematolymphoid malignancies. Clin Lymphoma Myeloma Leuk. 2017; 17: 834-851.
- 4Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol. 2006; 55: 897-900.
- 5Agterof MJ, Biesma DH. Bortezomib-induced skin lesions. N Engl J Med. 2005; 352: 2534.
- 6Gerecitano J, Goy A, Wright J, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol. 2006; 134: 391-398.
